thought call
surpris solid execut continu progress non-cf pipelin
investor await tripl combo data decis earn call larg
increment vertex solidli beat expect revenu ep
issu look conserv cf product revenu guidanc see
guidanc beatabl base discuss manag post call
seem addit ex-u agreement exclud guidanc
difficulti predict order time vertex anticip
new agreement end day view cf trajectori year
less import compar rapid progress tripl combo model
launch ye forecast continu view overal cf franchis
highli differenti transform impact look
beyond concern develop pace non cf pipelin seem
progress slowli overal came away call invest thesi
intact consequenti near term catalyst tripl combo phase data
cf remain track releas squar anticip strong data
ballpark seen tripl see thought
tripl phase data time file tripl combo nda
opportun upsid remain bullish share
reiter overweight rate price target
pipelin updat beyond cf phase data expect trial acut pain
potenti support pivot develop sickl cell arm
phase trial initi beta-th on-going antitrypsin
defici program enter clinic decemb first candid
focal segment glomerulosclerosi fsg plan
model adjust follow call left revenu
forecast unchang respect revis non-
gaap ep estim respect
quarterli annual ep usd
consensu number refinitiv receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
return equiti ttm
link barclay live interact chart
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
overweight anticip near-term growth
kalydeco follow fda decis includ
residu function mutat bolster approv
symdeko earlier overal top-lin growth
larg depend upon develop success
tripl combin phase data posit
phase set read-out submiss
faster expect uptak orkambi ou
favor price persist complianc trend
continu expans kalydeco new cf
popul robust uptak symdeko global
rapid develop tripl combin set
read phase data
stagnat ou orkambi neg
discuss regul delay launch
reduc price development delay stumbl
tripl combo rapid develop emerg
compet product approach gene-
price target updat pt base sum-of-th part npv analysi
forecast sale patent expir addit year potenti hatch-waxman
extens assum termin valu orkambi kalydeco symdeko tripl
combo risk adjust use discount rate forecast period
appropri reflect risk portfolio given assumpt assign valu
prior kalydeco prior orkambi prior
symdeko tripl prior combin pipelin valu
net cash prior result total npv
geoff meacham ph herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli
relat specif recommend view express research report
barclay research produc invest bank barclay bank plc affili collect individu barclay
author contribut research report research analyst unless otherwis indic public date top report
reflect local time report produc may differ releas date provid gmt
avail disclosur
compani subject research report current import disclosur regard compani pleas refer
http //publicresearch barclay com altern send written request barclay research complianc seventh avenu floor
new york ny call
analyst respons prepar research report receiv compens base upon variou factor includ firm total
revenu portion gener invest bank activ profit revenu market busi
potenti interest firm invest client research respect asset class cover analyst
analyst regularli conduct site visit view materi oper cover compani barclay polici prohibit accept
payment reimburs cover compani travel expens visit
barclay research depart produc variou type research includ limit fundament analysi equity-link analysi
quantit analysi trade idea recommend contain one type barclay research may differ contain
type barclay research whether result differ time horizon methodolog otherwis
procedur pleas
http //publicresearch barcap com/s/rd htm order access barclay research conflict manag polici statement pleas refer
price sourc refinitiv last avail close price relev trade market unless anoth time sourc indic
